Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”

Detalles Bibliográficos
Autores principales: Yamanishi, Tomonori, Kamasasko, Tomohiko, Kaga, Kanya, Fuse, Miki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354321/
https://www.ncbi.nlm.nih.gov/pubmed/32676385
http://dx.doi.org/10.21037/tau-2020-02
_version_ 1783558059604312064
author Yamanishi, Tomonori
Kamasasko, Tomohiko
Kaga, Kanya
Fuse, Miki
author_facet Yamanishi, Tomonori
Kamasasko, Tomohiko
Kaga, Kanya
Fuse, Miki
author_sort Yamanishi, Tomonori
collection PubMed
description
format Online
Article
Text
id pubmed-7354321
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73543212020-07-15 Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo” Yamanishi, Tomonori Kamasasko, Tomohiko Kaga, Kanya Fuse, Miki Transl Androl Urol Editorial Commentary AME Publishing Company 2020-06 /pmc/articles/PMC7354321/ /pubmed/32676385 http://dx.doi.org/10.21037/tau-2020-02 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Yamanishi, Tomonori
Kamasasko, Tomohiko
Kaga, Kanya
Fuse, Miki
Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title_full Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title_fullStr Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title_full_unstemmed Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title_short Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
title_sort editorial commentary on “safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo”
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354321/
https://www.ncbi.nlm.nih.gov/pubmed/32676385
http://dx.doi.org/10.21037/tau-2020-02
work_keys_str_mv AT yamanishitomonori editorialcommentaryonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo
AT kamasaskotomohiko editorialcommentaryonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo
AT kagakanya editorialcommentaryonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo
AT fusemiki editorialcommentaryonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo

Ejemplares similares